This document discusses concepts related to quality management and quality control in the pharmaceutical industry. It defines key terms like total quality management, quality assurance, and good manufacturing practices. It explains that quality should be built into products from the beginning of the production process through materials procurement, manufacturing, distribution, and obtaining customer feedback. It also outlines the objectives, systems, and components of quality management systems, including quality planning, risk management, corrective actions, and change control. Quality control is described as the system for ensuring proper testing and release of materials and products.
The document summarizes the process of bringing a new drug to market. It involves pre-clinical research for 4.5 years, clinical trials for 5 years, and seeking FDA approval for 2.5 years, for a total of 12 years. The estimated total cost is $800 million, including $335 million for pre-clinical research and $465 million for clinical trials and FDA approval. The process involves research and development teams, management, doctors, pharmacists, and clinical trial subjects working towards milestones of IRB proposal and approval, completing the three phases of clinical trials, and ultimately obtaining FDA approval to release the new drug to the market.
Stability indicating RP-HPLC method for estimation of dapagliflozin in bulk a...SriramNagarajan19
A simple, specific, accurate, precise and stability-indicating reverse phase high performance liquid chromatography (RP-HPLC) method is developed for estimation of Dapagliflozin (DGF) in bulk and Pharmaceutical dosage form. The method employed, Hypersil BDS C18 250 mm x 4.6 mm, 5 mm column in isocratic mode with mobile phase of 0.1% Ortho phosphoric acid buffer and acetonitrile 50:50% v/v. The flow rate was 1.0 mL min-1 and effluent was monitored at 245 nm using PDA detector. The injection volume was 10 µl and the total runtime was set as 5min. The retention time for DGF was found to be 2.226min.The method was validated in terms of Linearity, accuracy, precision, limit of detection (LOD), limit of quantification (LOQ) etc. in accordance with ICH guidelines. Linear regression analysis data for the calibration plot showed that there was a good linear relationship between response and concentration in the range of 25 - 150 µg/ml respectively. The LOD and LOQ values for HPLC method were found to be 0.04 and 0.121 µg/ml respectively. No chromatographic interference from the tablet excipients was found. The proposed method was successfully used for estimation of Dapagliflozin (DGF) in Bulk and Pharmaceutical dosage form.
This document provides an overview of the Investigational New Drug (IND) application process. It discusses how an IND is required to begin clinical trials on new drugs and allows pharmaceuticals to be transported between states for research purposes. The document outlines the various stages of pre-clinical and clinical testing, including pre-clinical studies in animals to establish safety, and the three phases of human clinical trials. It provides details on the key components of an IND application, including chemistry and manufacturing information, clinical protocols, and safety data from non-clinical studies. The overall goal of an IND is to obtain permission from the FDA to begin human clinical trials by demonstrating the new drug and trial design will not place subjects at unreasonable risk.
This document summarizes the objectives and classification system of the Global Harmonization Task Force (GHTF) for in vitro diagnostic (IVD) medical devices. The GHTF was founded in 1993 to harmonize medical device regulations globally. It aims to facilitate trade while preserving public health. IVD medical devices are classified into 4 risk-based classes (A to D) based on 16 general rules related to device invasiveness, energy use, and disease detection. Class A devices pose the lowest risk while Class D the highest. The classification system aims to ensure regulatory oversight is proportionate to device risk.
Clinical Research Regulation in European Union ShantanuThakre3
The document discusses clinical research regulations in the European Union. It provides information on the aim of the European Medicines Agency (EMA) in regulating clinical trials to protect subjects' rights and safety. It describes the EMA's role in ensuring good clinical practice standards across the European Economic Area. It also summarizes key points of the new Clinical Trials Regulation, including requirements for authorization, informed consent, and conducting trials on vulnerable groups. Finally, it discusses the Clinical Trials Information System that will support application and oversight of trials under the new Regulation.
Guideline on patient safety and well being in clinical trialsTrialJoin
Patient safety is and should be the number one priority in clinical research. Human participants in a clinical trial are necessary in order to improve and develop new therapies for certain conditions and advance the understanding of how a condition can be treated. Such medical advancements wouldn’t be possible without human subjects as participants. However, even though we all know the importance of clinical trials in the advancement of medicine, most people still have some misconceptions regarding this topic.
The feeling of being treated as a ‘’guinea pig’’ and fear of potential risks and side effects are still common among patients who suffer from a certain condition. Such misinformation and misconceptions regarding clinical trials can unnecessarily prevent patients from finding a potential cure or relief, and can also decrease the number of enrolled patients in studies.
In order to clarify these misunderstandings, we’ve decided to tell you everything there is to know about patient safety in clinical trials. We hope that with this information we can help you to better understand patient safety in clinical trials so that you gain more insight and start considering clinical trials as valid options that can help you improve any condition.
This document provides guidance on clinical investigation of medicinal products in pediatric populations. It outlines key issues to consider in pediatric drug development, including:
- Timing of pediatric studies based on disease severity and availability of alternative treatments
- Need for pediatric formulations that allow accurate dosing and enhance compliance
- Types of studies including pharmacokinetics, efficacy, and long-term safety
It also discusses important ethical considerations like informed consent, minimizing risk and distress, and recruitment. The addendum provides approaches to optimize pediatric drug development, such as using existing knowledge, extrapolation, and modelling/simulation to design efficient clinical trials. Special pediatric formulation needs for neonates are also addressed.
This document discusses concepts related to quality management and quality control in the pharmaceutical industry. It defines key terms like total quality management, quality assurance, and good manufacturing practices. It explains that quality should be built into products from the beginning of the production process through materials procurement, manufacturing, distribution, and obtaining customer feedback. It also outlines the objectives, systems, and components of quality management systems, including quality planning, risk management, corrective actions, and change control. Quality control is described as the system for ensuring proper testing and release of materials and products.
The document summarizes the process of bringing a new drug to market. It involves pre-clinical research for 4.5 years, clinical trials for 5 years, and seeking FDA approval for 2.5 years, for a total of 12 years. The estimated total cost is $800 million, including $335 million for pre-clinical research and $465 million for clinical trials and FDA approval. The process involves research and development teams, management, doctors, pharmacists, and clinical trial subjects working towards milestones of IRB proposal and approval, completing the three phases of clinical trials, and ultimately obtaining FDA approval to release the new drug to the market.
Stability indicating RP-HPLC method for estimation of dapagliflozin in bulk a...SriramNagarajan19
A simple, specific, accurate, precise and stability-indicating reverse phase high performance liquid chromatography (RP-HPLC) method is developed for estimation of Dapagliflozin (DGF) in bulk and Pharmaceutical dosage form. The method employed, Hypersil BDS C18 250 mm x 4.6 mm, 5 mm column in isocratic mode with mobile phase of 0.1% Ortho phosphoric acid buffer and acetonitrile 50:50% v/v. The flow rate was 1.0 mL min-1 and effluent was monitored at 245 nm using PDA detector. The injection volume was 10 µl and the total runtime was set as 5min. The retention time for DGF was found to be 2.226min.The method was validated in terms of Linearity, accuracy, precision, limit of detection (LOD), limit of quantification (LOQ) etc. in accordance with ICH guidelines. Linear regression analysis data for the calibration plot showed that there was a good linear relationship between response and concentration in the range of 25 - 150 µg/ml respectively. The LOD and LOQ values for HPLC method were found to be 0.04 and 0.121 µg/ml respectively. No chromatographic interference from the tablet excipients was found. The proposed method was successfully used for estimation of Dapagliflozin (DGF) in Bulk and Pharmaceutical dosage form.
This document provides an overview of the Investigational New Drug (IND) application process. It discusses how an IND is required to begin clinical trials on new drugs and allows pharmaceuticals to be transported between states for research purposes. The document outlines the various stages of pre-clinical and clinical testing, including pre-clinical studies in animals to establish safety, and the three phases of human clinical trials. It provides details on the key components of an IND application, including chemistry and manufacturing information, clinical protocols, and safety data from non-clinical studies. The overall goal of an IND is to obtain permission from the FDA to begin human clinical trials by demonstrating the new drug and trial design will not place subjects at unreasonable risk.
This document summarizes the objectives and classification system of the Global Harmonization Task Force (GHTF) for in vitro diagnostic (IVD) medical devices. The GHTF was founded in 1993 to harmonize medical device regulations globally. It aims to facilitate trade while preserving public health. IVD medical devices are classified into 4 risk-based classes (A to D) based on 16 general rules related to device invasiveness, energy use, and disease detection. Class A devices pose the lowest risk while Class D the highest. The classification system aims to ensure regulatory oversight is proportionate to device risk.
Clinical Research Regulation in European Union ShantanuThakre3
The document discusses clinical research regulations in the European Union. It provides information on the aim of the European Medicines Agency (EMA) in regulating clinical trials to protect subjects' rights and safety. It describes the EMA's role in ensuring good clinical practice standards across the European Economic Area. It also summarizes key points of the new Clinical Trials Regulation, including requirements for authorization, informed consent, and conducting trials on vulnerable groups. Finally, it discusses the Clinical Trials Information System that will support application and oversight of trials under the new Regulation.
Guideline on patient safety and well being in clinical trialsTrialJoin
Patient safety is and should be the number one priority in clinical research. Human participants in a clinical trial are necessary in order to improve and develop new therapies for certain conditions and advance the understanding of how a condition can be treated. Such medical advancements wouldn’t be possible without human subjects as participants. However, even though we all know the importance of clinical trials in the advancement of medicine, most people still have some misconceptions regarding this topic.
The feeling of being treated as a ‘’guinea pig’’ and fear of potential risks and side effects are still common among patients who suffer from a certain condition. Such misinformation and misconceptions regarding clinical trials can unnecessarily prevent patients from finding a potential cure or relief, and can also decrease the number of enrolled patients in studies.
In order to clarify these misunderstandings, we’ve decided to tell you everything there is to know about patient safety in clinical trials. We hope that with this information we can help you to better understand patient safety in clinical trials so that you gain more insight and start considering clinical trials as valid options that can help you improve any condition.
This document provides guidance on clinical investigation of medicinal products in pediatric populations. It outlines key issues to consider in pediatric drug development, including:
- Timing of pediatric studies based on disease severity and availability of alternative treatments
- Need for pediatric formulations that allow accurate dosing and enhance compliance
- Types of studies including pharmacokinetics, efficacy, and long-term safety
It also discusses important ethical considerations like informed consent, minimizing risk and distress, and recruitment. The addendum provides approaches to optimize pediatric drug development, such as using existing knowledge, extrapolation, and modelling/simulation to design efficient clinical trials. Special pediatric formulation needs for neonates are also addressed.
Protocol Design & Development: What You Need to Know to Ensure a Successful S...Brook White, PMP
Solid protocol design is critical to clinical development. No matter how well executed a clinical study is, if the underlying design is flawed, it wasn’t worth doing. In this presentation, Dr. David Shoemaker, SVP R&D, and Dr. Karen Kesler, AVP Operations, will walk through the process of developing a protocol, explain the major considerations, and point out common mistakes and challenges.
This document provides guidance for preparing Standard Operating Procedures (SOPs) in the pharmaceutical industry. It discusses the benefits of SOPs, which include ensuring quality and consistency, compliance with regulations, and serving as training documents. The document outlines the typical process for developing, reviewing, revising and controlling SOPs. This includes writing SOPs, reviewing and approving them, determining the frequency of revisions, using checklists, and document tracking. It also provides guidelines for the content and structure of technical and administrative SOPs.
Quality assurance is the responsibility of the sponsor to ensure clinical trials are conducted properly according to regulations. It involves implementing quality control systems and allowing audits and inspections. Audits independently check that the study, data, patient safety, and regulatory compliance are accurate. Inspections allow regulatory authorities to review documents, facilities, and records. Proper preparation is key, such as having all required documents organized and understanding the protocol. Mistakes are common but can be prevented by understanding good clinical practice principles and having open communication.
clinical trial Management with ethics committeeSrinivasanBB
The document discusses key aspects of clinical trial management including experimental units, treatment and evaluation, approaches to clinical trials, the roles of various organizations, and essential documents. It provides definitions for experimental units and outlines how treatments and evaluations are conducted in clinical trials. It describes the trial approach process including principal investigators, feasibility questionnaires, ethics committee approval, and registration. It also outlines the roles of site management organizations, ethics committees in reviewing protocols and risks/benefits, and regulatory requirements in India including the Drug and Cosmetic Act, regulatory bodies, and the application process. Finally, it discusses important documents for conducting and reporting clinical trials.
To ensure FDA readiness, companies must develop a plan to ensure that they are in compliance during inspections, and reduce the likelihood of receiving warning letters.
A standard for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of clinical trials that provide assurance that the data and the reported results are credible (able to be believed), accurate and that the rights, integrity and confidentiality of trial subjects are protected.
Deconstructing all types of monitoring visitsDan Sfera
There are four types of monitoring visits for clinical trials: site selection visits, site initiation visits, interim monitoring visits, and close out visits. Site selection visits involve touring facility and assessing capabilities. Site initiation visits focus on training, delegation, supply receipt, and system access. Interim monitoring visits review protocol compliance, safety reporting, data verification, and recruitment. Close out visits include reconciling supplies, closing safety reports, finalizing data, and archiving documents.
The document outlines the responsibilities of an investigator in clinical trials. An investigator is responsible for leading the clinical trial team and ensuring compliance with regulations. Key responsibilities include obtaining necessary approvals, ensuring safety of trial subjects, obtaining informed consent, accurately collecting and reporting data, and protecting subjects' rights and well-being. Maintaining high ethical standards in clinical trials is important to generate credible results and provide assurance to the public.
QbD Model Case Study of MONOCLONAL ANTIBODY : A-Mab.Shivang Chaudhary
The A-Mab Case Study involved the efforts of many individuals from CMC-BWG and would not have been made possible if it were not for the countless number of hours spent by the 5 participating companies (GlaxosmithKline, MedImmune, Merck, Pfizer, PWC and sanofi pasteur).
The document defines key terms related to clinical trial monitoring such as monitoring, monitoring visits, and monitoring reports. It describes the purpose of monitoring is to protect subjects, ensure accurate data, and ensure compliance. It discusses selecting qualified monitors and different types of monitoring visits including site evaluation, initiation, routine monitoring, and close-out visits. The key responsibilities of monitors during visits are also summarized.
Project management in clinical research sanjay akhani 8 maySanjay Akhani
This document discusses project management in clinical research. It begins with a disclaimer from the presenter. It then provides an overview of key aspects of project management in clinical research, including project management tools and techniques used, components of a project management plan, managing contract research organizations and site management organizations, optimizing patient recruitment, and working with remote and multicultural teams. Challenges of working with remote and multicultural teams include differences in communication styles, work ethics, decision making, and views of time and change due to cultural differences between high and low context cultures.
Handling of a fda inspection [compatibility mode]Kiran Kota
The document provides guidance on handling FDA inspections. It discusses key points like signing the FDA Form 482 notice, having subject matter experts available to answer questions, and reviewing documentation before providing it to inspectors. It also describes the FDA's quality system inspection approach, the different inspection classifications (NAI, VAI, OAI), and what is contained in the Establishment Inspection Report provided after an inspection.
The document discusses guidelines for clinical trial protocols according to various regulatory agencies. It provides definitions of a protocol, describes common components of protocols such as objectives, study design, and safety assessments. It also outlines regulatory requirements for bioequivalence studies from agencies like FDA, EMA, and CDSCO regarding issues like study design, sample size, acceptance criteria, product handling and more. Requirements for conducting fed and fasting studies are also covered.
Post-marketing surveillance (PMS) involves monitoring pharmaceutical drugs and medical devices after they have been released to the public to identify adverse drug reactions (ADRs) that were not detected in pre-market clinical trials due to limitations such as narrow study populations and durations. PMS benefits include identifying low frequency ADRs, effects in high risk groups, long term effects, and drug interactions. Information is collected through expert user groups, customer surveys, complaints, literature reviews, and media reports. PMS studies use controlled clinical trials, spontaneous reporting, cohort studies, and case control studies to identify drug effects.
Drug accountability: an important aspect of clinical researchTrialJoin
Drug accountability is an interesting topic related to clinical research, both for the CRAs and for the clinical research sites. Even though drug accountability isn’t a task that should be performed by the CRA, he or she is still responsible for monitoring and making sure that the site is correctly performing every task related to this field.
The topic of drug accountability is especially important in regards to quality data as well as for patient safety. For this reason, we’ll give you an in-depth explanation of everything that drug accountability entails.
The document summarizes the regulation of in vitro diagnostic (IVD) medical devices in Australia. It outlines the regulatory framework, classification system, conformity assessment process, and key aspects of an inclusion application for IVD devices to be entered into the Australian Register of Therapeutic Goods (ARTG). The summary highlights that IVD devices are regulated under the Therapeutic Goods Act and must comply with essential principles, be appropriately classified, and have evidence of conformity assessment submitted with ARTG applications, which may be subject to audit.
The document describes a proposed website called "Freebirds" that allows solo travelers to connect and plan trips together. Key points:
- The website would allow users to create profiles, join or start travel groups, and collaboratively plan trips by scheduling activities, booking reservations, and sharing photos.
- Revenue would come from advertisements and commissions from reservations booked through the site.
- Interviews with potential users found that most were interested but had some concerns about safety and wanted security verification of other travelers.
- A graduate student provided recommendations from an HCI perspective including improving color contrast, font readability, task orientation, and overall design simplicity.
Top 5 Warning Signs Your Clinical Trial Is Off TrackDavid Levin
This document discusses risk management in clinical trials. It outlines a four-step process for risk management: risk assessment and analysis, risk mitigation, risk measurement, and risk management. It provides examples of early warning signs to look for during study start-up and operations, how to measure those risks, and how to address risks that become issues. Some potential risks discussed include slower than expected enrollment, poor site compliance, and breakdown of sponsor-CRO relationships.
Protocol Design & Development: What You Need to Know to Ensure a Successful S...Brook White, PMP
Solid protocol design is critical to clinical development. No matter how well executed a clinical study is, if the underlying design is flawed, it wasn’t worth doing. In this presentation, Dr. David Shoemaker, SVP R&D, and Dr. Karen Kesler, AVP Operations, will walk through the process of developing a protocol, explain the major considerations, and point out common mistakes and challenges.
This document provides guidance for preparing Standard Operating Procedures (SOPs) in the pharmaceutical industry. It discusses the benefits of SOPs, which include ensuring quality and consistency, compliance with regulations, and serving as training documents. The document outlines the typical process for developing, reviewing, revising and controlling SOPs. This includes writing SOPs, reviewing and approving them, determining the frequency of revisions, using checklists, and document tracking. It also provides guidelines for the content and structure of technical and administrative SOPs.
Quality assurance is the responsibility of the sponsor to ensure clinical trials are conducted properly according to regulations. It involves implementing quality control systems and allowing audits and inspections. Audits independently check that the study, data, patient safety, and regulatory compliance are accurate. Inspections allow regulatory authorities to review documents, facilities, and records. Proper preparation is key, such as having all required documents organized and understanding the protocol. Mistakes are common but can be prevented by understanding good clinical practice principles and having open communication.
clinical trial Management with ethics committeeSrinivasanBB
The document discusses key aspects of clinical trial management including experimental units, treatment and evaluation, approaches to clinical trials, the roles of various organizations, and essential documents. It provides definitions for experimental units and outlines how treatments and evaluations are conducted in clinical trials. It describes the trial approach process including principal investigators, feasibility questionnaires, ethics committee approval, and registration. It also outlines the roles of site management organizations, ethics committees in reviewing protocols and risks/benefits, and regulatory requirements in India including the Drug and Cosmetic Act, regulatory bodies, and the application process. Finally, it discusses important documents for conducting and reporting clinical trials.
To ensure FDA readiness, companies must develop a plan to ensure that they are in compliance during inspections, and reduce the likelihood of receiving warning letters.
A standard for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of clinical trials that provide assurance that the data and the reported results are credible (able to be believed), accurate and that the rights, integrity and confidentiality of trial subjects are protected.
Deconstructing all types of monitoring visitsDan Sfera
There are four types of monitoring visits for clinical trials: site selection visits, site initiation visits, interim monitoring visits, and close out visits. Site selection visits involve touring facility and assessing capabilities. Site initiation visits focus on training, delegation, supply receipt, and system access. Interim monitoring visits review protocol compliance, safety reporting, data verification, and recruitment. Close out visits include reconciling supplies, closing safety reports, finalizing data, and archiving documents.
The document outlines the responsibilities of an investigator in clinical trials. An investigator is responsible for leading the clinical trial team and ensuring compliance with regulations. Key responsibilities include obtaining necessary approvals, ensuring safety of trial subjects, obtaining informed consent, accurately collecting and reporting data, and protecting subjects' rights and well-being. Maintaining high ethical standards in clinical trials is important to generate credible results and provide assurance to the public.
QbD Model Case Study of MONOCLONAL ANTIBODY : A-Mab.Shivang Chaudhary
The A-Mab Case Study involved the efforts of many individuals from CMC-BWG and would not have been made possible if it were not for the countless number of hours spent by the 5 participating companies (GlaxosmithKline, MedImmune, Merck, Pfizer, PWC and sanofi pasteur).
The document defines key terms related to clinical trial monitoring such as monitoring, monitoring visits, and monitoring reports. It describes the purpose of monitoring is to protect subjects, ensure accurate data, and ensure compliance. It discusses selecting qualified monitors and different types of monitoring visits including site evaluation, initiation, routine monitoring, and close-out visits. The key responsibilities of monitors during visits are also summarized.
Project management in clinical research sanjay akhani 8 maySanjay Akhani
This document discusses project management in clinical research. It begins with a disclaimer from the presenter. It then provides an overview of key aspects of project management in clinical research, including project management tools and techniques used, components of a project management plan, managing contract research organizations and site management organizations, optimizing patient recruitment, and working with remote and multicultural teams. Challenges of working with remote and multicultural teams include differences in communication styles, work ethics, decision making, and views of time and change due to cultural differences between high and low context cultures.
Handling of a fda inspection [compatibility mode]Kiran Kota
The document provides guidance on handling FDA inspections. It discusses key points like signing the FDA Form 482 notice, having subject matter experts available to answer questions, and reviewing documentation before providing it to inspectors. It also describes the FDA's quality system inspection approach, the different inspection classifications (NAI, VAI, OAI), and what is contained in the Establishment Inspection Report provided after an inspection.
The document discusses guidelines for clinical trial protocols according to various regulatory agencies. It provides definitions of a protocol, describes common components of protocols such as objectives, study design, and safety assessments. It also outlines regulatory requirements for bioequivalence studies from agencies like FDA, EMA, and CDSCO regarding issues like study design, sample size, acceptance criteria, product handling and more. Requirements for conducting fed and fasting studies are also covered.
Post-marketing surveillance (PMS) involves monitoring pharmaceutical drugs and medical devices after they have been released to the public to identify adverse drug reactions (ADRs) that were not detected in pre-market clinical trials due to limitations such as narrow study populations and durations. PMS benefits include identifying low frequency ADRs, effects in high risk groups, long term effects, and drug interactions. Information is collected through expert user groups, customer surveys, complaints, literature reviews, and media reports. PMS studies use controlled clinical trials, spontaneous reporting, cohort studies, and case control studies to identify drug effects.
Drug accountability: an important aspect of clinical researchTrialJoin
Drug accountability is an interesting topic related to clinical research, both for the CRAs and for the clinical research sites. Even though drug accountability isn’t a task that should be performed by the CRA, he or she is still responsible for monitoring and making sure that the site is correctly performing every task related to this field.
The topic of drug accountability is especially important in regards to quality data as well as for patient safety. For this reason, we’ll give you an in-depth explanation of everything that drug accountability entails.
The document summarizes the regulation of in vitro diagnostic (IVD) medical devices in Australia. It outlines the regulatory framework, classification system, conformity assessment process, and key aspects of an inclusion application for IVD devices to be entered into the Australian Register of Therapeutic Goods (ARTG). The summary highlights that IVD devices are regulated under the Therapeutic Goods Act and must comply with essential principles, be appropriately classified, and have evidence of conformity assessment submitted with ARTG applications, which may be subject to audit.
The document describes a proposed website called "Freebirds" that allows solo travelers to connect and plan trips together. Key points:
- The website would allow users to create profiles, join or start travel groups, and collaboratively plan trips by scheduling activities, booking reservations, and sharing photos.
- Revenue would come from advertisements and commissions from reservations booked through the site.
- Interviews with potential users found that most were interested but had some concerns about safety and wanted security verification of other travelers.
- A graduate student provided recommendations from an HCI perspective including improving color contrast, font readability, task orientation, and overall design simplicity.
Top 5 Warning Signs Your Clinical Trial Is Off TrackDavid Levin
This document discusses risk management in clinical trials. It outlines a four-step process for risk management: risk assessment and analysis, risk mitigation, risk measurement, and risk management. It provides examples of early warning signs to look for during study start-up and operations, how to measure those risks, and how to address risks that become issues. Some potential risks discussed include slower than expected enrollment, poor site compliance, and breakdown of sponsor-CRO relationships.
Launch Team Training Workbook for Hartford City Covenant Church, CTJason Condon
This document provides information for a launch team training day for a new church plant in Hartford, Connecticut called Hartford City Covenant Church. It includes details about the agenda for the day which will include introductions, a devotional, information about the supporting denominations including the East Coast Conference and Evangelical Covenant Church, and a discussion of the vision and values for the new church. The training aims to help the launch team understand how the new church will fit within and be supported by the larger network of churches and denominations.
Suzanne Pozsonyi MedicReS World Congress 2013MedicReS
1. The document outlines the key study preparation and start up activities that are typically the responsibility of sponsors and CROs.
2. It discusses feasibility studies, site selection, pre-study visits, contracting, submitting documents to ethics committees, training, and initiation visits.
3. The purpose of these activities is to ensure clinical sites and investigators are properly qualified and prepared to conduct the study according to regulatory standards and the study protocol.
Faster Clinical Trials Study Startup Time Gives Real RoiAlasdair Kilgour
This document discusses the use of clinical document exchange portals to improve efficiency in clinical trial study start-up processes. It notes that study start-up is often inefficient and a bottleneck, costing time and money. Online document management portals can help by providing a centralized, collaborative environment for sharing documents. This allows sites, sponsors and CROs to more easily track documents, access the latest versions, and monitor study start-up progress in real-time. However, moving to these systems also faces challenges around adoption, training needs and investment costs that must be considered. Key elements for successful implementation include the portal being centralized, web-based, user-friendly and cost-effective.
Academy of Management Study Examines Successful Start-Up Strategies Nina Aversano
The document discusses a study published in the Academy of Management Journal that examined strategies for successful start-ups. The study found that hybrid start-ups, which are gradually launched part-time, were less likely to fail long-term compared to start-ups launched full-time. This may be because hybrid start-ups mitigate risk and allow for longer preparation. The findings contrast stereotypes of entrepreneurs taking big risks and instead support a more risk-tolerant approach of gradually building a business over time.
This document provides steps for creating a start-up business, including coming up with an idea, defining goals, getting registered, developing a business plan, performing competitor analysis, creating a development plan, hiring professionals, and launching the business. It emphasizes important questions that must be answered such as what makes the company different, whether the right team is in place, how the business will make money, and the size of the target market. The document concludes by instructing groups to come up with potential Guyanese businesses and answer these key questions.
This document discusses the process of starting up a clinical trial from a global perspective. It provides statistics on clinical trial start-up times and outlines the various steps involved in the start-up process, including conducting feasibility assessments of potential sites, following up with sites, ensuring contract and budget requirements are met, and working towards fully enrolling sites and reaching the finish line. Key aspects that are important for clinical research associates to focus on during start-up include understanding study details and ensuring site feasibility responses and enrollment projections are accurate.
This presentation details how medical device companies can utilize enrollment planning tactics to ensure the optimal cost and time for their clinical trials.
The presentation I made for my talk at AlleyNYC on building teams in early stage technology startups. Be sure to read the comments on each of the slides as they add additional information to what is presented on the slide.
Why creating a start-up makes sense? TAIEX Moldova - June 2013Pim de Bokx
During this conference in Chisinau (Capital of Moldova) I shared my vision and experience on why start-ups make sense for any economy and how success rates can be upgraded by effective incubation programs. In this workshop we also brainstormed about how the performance of incubation can be measured real-time!
Our audience in Chisinau came from government, academia, incubation, finance and business. I was honored to be invited by TAIEX (European Technical Assistance bureau) to come over and share my experience. It was my first time there and hope it won't be my last time.
A presentation to the Student Government Councils of local universities and colleges in Malaysia was presented by Michael Teoh, surrounding the topics of Teamwork and Leadership.
This workshop for Student Leaders was done back in 2005 and 2006.
The document discusses lessons learned from building a 130+ person team at Moz. It provides 8 key lessons: 1) You can coach employees' skills but not their passion for the work. 2) Startups often make wrong hiring choices. 3) Company culture is defined by who is hired, promoted, and rewarded, not superficial perks. 4) Titles and management roles should not be the only path for influence. 5) Build a recruiting brand beyond just the product. 6) Beware of gimmicks like bonuses that can hurt company culture. 7) Create a clear vision and expectations that everyone understands. 8) Establish mechanisms for regular, structured feedback as the company scales.
Clinical Trial Requirements U.S. vs. EU Similarities and DifferencesRETIRE
The document provides an overview of the key similarities and differences between clinical trial requirements in the United States and European Union. Some of the main differences include: in the US, IND approval is not required to begin a trial but the EU requires CTA approval; the US allows protocol waivers under certain conditions while the EU considers waivers a breach of GCP; and adverse event reporting timelines are generally shorter in the EU. Record keeping requirements for documents and investigational products also differ between the regions.
This document provides an overview of building high performing teams. It defines a team and outlines Tuckman's four stages of team development: forming, storming, norming, and performing. Developing high performance requires strong leadership to provide direction and inspire the team. It also requires understanding team members' strengths and roles. Finally, teams must establish effective methods of communication, problem solving, and conflict resolution. Regular assessment and maintenance is needed to sustain team performance over time.
OVERVIEW:
For many years now, organizations across the globe have come to realize the significance of working as a team. Studies have shown that organizations optimize their performances when all members of the team are imbued with a common goal and the spirit of cooperation. However, transforming a group of loosely-connected employees into a dynamic and synergistic team is a process that seldom occurs naturally. Hence, this particular teambuilding workshop was developed to facilitate this transformation.
“The 7 Essentials of Teamwork” develops teams by teaching the members of the team how to apply the seven essentials that make a team effective. This team-building workshop is a loose adaptation of Patrick Lencioni’s bestselling book, “The 5 Dysfunctions of a Team”. This workshop will help teams identify their problems dysfunction and learn ways to overcome them. It will also help teach leaders their roles in the team and the styles to use to achieve each essential. It will also teach members their responsibilities to the team and ensure that the team is continuously progressing and moving forward.
OBJECTIVES:
At the end of the training program, the participants will be able to:
1. Develop trust and cohesiveness in the team by understanding their weaknesses and appreciating their strengths
2. Connect with each other better by enhancing team communication and acquiring conflict management skills;
3. Learn to commit to the team and its targets, especially understanding the leaders’ and members’ contribution to the goals of the organization;
4. Learn how to be accountable for their roles and responsibilities and hold each other accountable in a professional way; and
5. Learn how to focus on attaining the goals and results set by the organization
Clinical research involves conducting research studies in human volunteers to answer health questions and find new treatments. It typically involves several phases from preclinical testing in animals to clinical trials in human subjects. India is emerging as a global hub for clinical research due to its large patient pools, low costs, and trained professionals. However, there is a large gap between the growing demand for trained clinical research professionals and current supply. Cliniminds aims to address this need by providing a wide range of clinical research training programs and courses.
This presentation explains how to play some team building activities that are important to the effective management and growth of teams and their objectives.
This document discusses the clinical trials process from protocol development through study completion. It covers developing the protocol, regulatory documents, patient recruitment, safety reporting, interim reports, and end of study activities. Key aspects include writing an approvable protocol, establishing an investigator site file, screening and enrolling suitable patients, maintaining safety oversight, and conducting closeout procedures. The goal is to provide guidance on managing all stages of a clinical trial.
Lwanda Vuyisile Bam is a South African citizen residing in Kempton Park. He has experience working as a junior project manager and project coordinator. His education includes a partially completed sports management diploma from Varsity College and a journalism diploma. He is proficient in English and has excellent computer skills.
Emily Angevine has over 10 years of experience in clinical research. She holds a B.S. in Recreational Therapy and has advanced through roles at PPD from Project Assistant to her current role as Senior Country Approval Specialist. She prepares, reviews, and coordinates local regulatory submissions and develops submission strategies. Previously she coordinated administrative functions and ensured regulatory compliance as a Principal Project Assistant, Senior Project Assistant, and Project Assistant II.
This document provides an overview of project scheduling concepts and best practices. It discusses the purpose of a project schedule as a management communication tool [SENTENCE 1]. It covers schedule strategy, including building a schedule on paper before entering it into software. The document also discusses scheduling software options, certification in project scheduling through PMI, and tips for preparing for the PMI Scheduling Professional exam [SENTENCE 2]. Project scheduling concepts discussed include work breakdown structures, critical path method, appropriate level of detail in a schedule, and regularly updating the schedule [SENTENCE 3].
Minette Griffiths is a 46-year-old project manager seeking new opportunities. She has over 20 years of experience managing projects in various industries including banking, insurance, retail, and manufacturing. Her education includes an MBA in progress and various project management certifications. She is proficient in Microsoft Office, PMBOK methodologies, and has experience with Prince2, Agile, and other frameworks. Her CV provides details on her past roles and responsibilities managing multi-million rand projects for companies like Ares Africa, JD Group, SAB Miller, and i5. References are available upon request.
Florence Kalipa is a Project Manager with over 14 years of experience in project management and business analysis. She holds a Bachelor's degree in Computer Science and qualifications in project management and business analysis. She is currently working as a Senior Project Manager at Investec and has experience managing projects in the financial services industry using Agile and waterfall methodologies.
The document provides an overview of the program management framework for Client X's B/OSS program. It describes the program governance structure including roles and responsibilities. It also outlines key PMO processes like action item management, issue management, decision management, and status reporting. The processes are described along with templates and artifacts that will be used to track items and reporting.
The document provides guidance on techniques for turning troubled projects around from being over budget and behind schedule to being successful. It discusses conducting an inheritance review to understand project status, creating a 100-day plan to get the project back on track in the short term, using mapping and planning techniques to establish a new baseline, and having honest conversations with stakeholders to manage expectations. Communication is emphasized as key to recovering projects and maintaining stakeholder confidence.
PA- 210-G5-Preparing of Project Proposal and other Related needs for the Impl...MarivicPenarubia1
This document outlines the steps for preparing project proposals and implementing development projects in the Philippines. It discusses preparing a project proposal, follow up work for approval, and planning implementation. Preparing a proposal involves defining the problem, presenting a solution, outlining deliverables and success criteria, stating the plan and schedule/budget. Follow up ensures projects meet objectives and builds accountability. Planning implementation requires defining goals, conducting research, mapping risks, assigning tasks, and allocating resources. The overall goal is to effectively develop and oversee projects to improve economic and social conditions.
This document contains a resume for Tolentino Genita Ryan Voltaire. It summarizes his work experience, education, licenses, skills and training. He has over 12 years of experience in civil engineering, safety engineering, project management and quality control. His most recent role was as a Senior Project Director in Saudi Arabia where he oversaw multiple construction projects worth over $50 million. He holds professional licenses in civil engineering and speaks English fluently.
The document provides information about an upcoming training for the Alcohol Prevention Project (APP) Implementation from September 30 to October 8. It discusses getting started with the implementation process, including reviewing materials and guidance documents. The training objectives are listed as understanding the four core areas of implementation in the Strategic Prevention Framework, describing the functions and purpose of the APP Implementation Process, and applying the three parts of the Implementation Plan. An agenda outlines topics to be covered during the training.
This document discusses project management and provides information about defining, planning, executing, monitoring, and closing projects. It defines what a project is and lists some key characteristics. It explains that projects have objectives that should be specific, measurable, agreed upon, realistic and time-related. The document also discusses challenges that can impact projects like costs, quality, time, organizational politics and external issues. It describes the tasks of a project manager and phases in a project life cycle.
This document provides a summary of Gabriela Corona's professional experience and qualifications. She has over 16 years of experience in communications, education, administration, and management. Her most recent role is as a Project Manager at Configure Inc., where she is responsible for developing and implementing projects, communicating status updates, and ensuring projects are delivered on time and on budget. Prior experience includes roles as a Professor, Sales Representative, Marketing Coordinator, and Electoral Trainer. She has a Bachelor's degree in Communication from UTEP and is proficient in Microsoft Office, Project Management, and various teaching and business skills.
Holland Study - Implementation Plan (PDF).pdfrozilawati
The document provides a draft implementation plan for recommendations from a management study of the City of Holland. It includes 28 recommendations across various city departments grouped into priority levels. For each recommendation, it outlines implementation steps, estimated time to accomplish, and person responsible. The plan is intended to serve as a tool to help the city systematically implement the initiatives from the management study.
The document discusses project implementation, including defining it as converting project inputs to outputs. It outlines key phases like project activation and operation. A project implementation plan is described as including a schedule, roles, stakeholder participation, structure, finances, reporting, and sustainability. Methods for implementation planning like Gantt charts are explained. Factors affecting success and challenges are listed. Effective management of implementation is emphasized as setting up systems and offices, recruiting staff, defining responsibilities, and establishing records and financial procedures.
This document discusses how to apply lean principles to project management. It begins with an overview of project management basics like the project lifecycle and key knowledge areas. It then covers lean concepts such as the seven types of waste and 5S. The document proposes integrating lean tools into each stage of a project, such as using a visual board ("Obeya") for planning and daily stand-ups ("huddles") for monitoring progress. The overall message is that combining lean thinking with established project management practices can help complete projects faster, with fewer defects and higher customer satisfaction.
This document provides an overview of project management fundamentals and how VCU has established a Project Management Office (PMO) and methodology to meet requirements under the Restructured Higher Education Financial and Administrative Operations Act Tier 3. Key points covered include:
- The phases of project management including initiation, planning, execution, control, and closeout.
- VCU's PMO was created to ensure best practices are followed and provide governance over project submission, selection, and prioritization.
- A task force developed VCU's project management methodology by researching best practices and requirements for managing projects and IT.
- Projects are classified based on complexity, budget, time, and resources to determine management approach.
This document outlines the process and procedure for monitoring outcomes and processes in CDCD Programme ICS_Cambodia Office projects. It discusses tools like the Activities Completion Report, Monthly Progress Report, and Consolidated Monthly Report that are used to track activities, outputs, and budgets against plans. Outcome monitoring focuses on changes in knowledge, attitudes, practices, policies and systems using tools such as quarterly and annual reports. The monitoring data is collected, consolidated, and analyzed to provide early feedback on progress and make adjustments if needed.
This document provides a summary of L. Douglas Sargent Jr.'s experience and qualifications. He has over 38 years of experience in construction management, including 24 years as a senior project manager. He has extensive experience managing data center, commercial, industrial, and government construction projects. His responsibilities have included budgeting, scheduling, procurement, quality control, and client relations. He is proficient in various construction software programs and holds several industry certifications.
The working group will be responsible for finalizing, testing, evaluating, updating and improving the contingency plan (CP). It will facilitate meetings with planners and experts to develop the CP and present it to authorities for approval. The working group members include a head, facilitator, secretariat, and cluster representatives who will complete implementation plans for their clusters. Once completed, the working group will endorse the final CP to relevant authorities.
1. Site Start-Up Team Lead General Training Presentation By Navdeep Mahajan 1
2. Site Start Up 2 Identification of Sites IP Release Site Contract Negotiation Regulatory & Ethics Submissions A D C B Contract Negotiation and Execution of all Site Contracts IP Release Site ID Ethics and/or Regulatory Submissions and Translations SSU Timeline: Post Award Site ID –> IP Release
8. Responsibilities Primary Contact for global CTL, PM and RTL. Develop Start-Up Project Plan Ensure Uniform Standards are applied Design Project Instructions – SSU Activities Assess Project Risks and develop contingency plan (For Start-up Part ONLY) 6
9. Responsibilities Present Updates on a weekly meeting to Global Team and/or Sponsor Manage Weekly meeting with Local SSU teams for updates and project progress/planning Encourage and Support Issue Escalation Track Study progress using various tools like CI, and weekly meetings 7
10. Responsibilities Track Team Performance and highlight performance issues at the right time to LMs Responsible for Project Specific Training, Mentoring and supervising the Local SSU teams Accountable for ALL SSU Deliverable and Timelines Conduct “Lessons Learned” after SSU Closeout 8
16. Brief protocol overview, etc. SSU lead will be required to make a presentation on SSU activities, resources and expertise during these meetings. 10
17. The Work Flow 2. Project Planning Set up goals for self and the team. Arrange for weekly team meetings. Arrange for methods on receiving and providing study updates. Arrange for Site Identification. Plan Ethics Committee/Regulatory Authority Submissions. Plan for Contracts and Investigator Budget. Project Instructions for Investigational Product release documents (Essential Documents) and any other SSU activities where required. 11
18. The Work Flow 3. Project Execution Ensure weekly meetings are conducted throughout the start up phase and get updates from local SSU team Ensure to attend weekly Sponsor/Global Team Calls and provide most recent updates. Ensure all activities are proceeding as per plan and any delays seen must be addressed immediately Track all project delays from Sponsor or global team closely, as these would affect the team and individual metrics. 12
19. The Work Flow 3. Project Execution (Cont.) Ensure all critical documents (ex: EC Approvals, RA Approvals, Export Licenses, etc.) are reviewed as and when they have been received to avoid surprises towards the time of IP release. Manage ICF finalizations and Translations. Manage Staff Transitions if any during this period. Primarily responsible for Contract negotiation with sites that have been not managed by SSU staff. 13
20. The Work Flow 3. Project Execution (Cont.) QC for the IP release documents (may need to sign as reviewer/approver depending on agreement with CTL/PM). Ensure all activities being undertaken are as per the scope agreed and any out of scope activities must be captured in and shared with the PM towards the end of Start up activities or as and when a change order is due. 14
21. The Work Flow 4. Project Close-Out (All SIVs Complete) Ensure all Contracts have been executed and copies of these have been Filed. Ensure all Site Handovers have been completed and sent to CRA/CTL. Ensure you have received confirmation from PM/CTL on wrap up of SSU activities Track your metrics “Lessons Learned” Session for entire team 15
23. Challenges Understanding each country Regulatory Requirements and the environment Understanding Cultural Difference in handling teams Understanding that SSU is still in it’s INFANCY in many companies and in the region and hence processes are not yet streamlined Usually regional roles require a lot of multi-tasking and appropriate delegation Timely follow up due to different holiday periods Constant mentoring and eliciting high performance 17
25. Lessons Always and Always Set Realistic Timelines in consultation with Local SSU teams and their LMs Never over commit even if it appears to be possible by Stretching Manage Performance right from the start of the study and escalate any non performing resource/ team to line managers Have a weekly call with the full SSU team or by country to get updates other than via emails and CI. Keep the communication channel transparent Identify your back up while you are on planned leave well in advance 19
26. Lessons Highlight Potential Delays in Start up right at the KO meeting. Track all out of scope activities Ensure adequate and proper training is provided to the local SSU teams. Involve in Contract Negotiations where required and not for every site. Review of Critical documents real time. 20
27. Some DON’Ts SSU Lead is not part of the Investigator Budget finalization. We only negotiate the provided Budget! SSU Lead will not take onus for responding to EC queries related to the Protocol. We will only facilitate the queries between site – sponsor! SSU Lead will not assist in Investigator Meeting related activities nor the CRA training! SSU Lead will not be part of detailed Protocol training! SSU lead will not review the Master ICF with respect to the protocol and will review it only for GCP and Local requirements! 21
28. Some DON’Ts SSU Lead will not involve in justification for export and Import Licenses SSU Lead will only assist in RA Submissions unless no CTL is identified at that time. SSU Lead will not be responsible for queries from sites after SSV related to protocol. 22